Beike Biotechnology
Stem cell therapy for neuropathy in China typically costs between $9,000 and $20,000. Total expenses depend on the number of cell injections and the required treatment cycles. In the United States, patients often pay around $25,000 for similar protocols. Choosing China provides average savings of 42%. Programs generally include laboratory cell preparation and pre-treatment diagnostics.
Bookimed Expert Insight: Quality often depends on laboratory standards rather than just clinic size. Beike Biotechnology in Shenzhen stands out due to its CNAS and ISO 9001 certifications. They utilize GMP-standard laboratories and a unique traceability system for every cell package. This level of technical oversight has supported nearly 50 peer-reviewed papers. Choosing facilities with such documented research ensures the treatment follows rigorous scientific protocols.
| China | Turkey | Austria | |
| Stem cell therapy for neuropathy | ≈ $9,000 | from $7,000 | ≈ $5,500 |
No hidden fees – just official clinic prices. Pay at the clinic for Stem cell therapy for neuropathy upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Stem cell therapy for neuropathy and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Stem cell therapy for neuropathy journey.
Dr. Sean Hu is a leader in biotechnology and stem cell therapy. He earned a PhD in biochemistry and molecular biology from the University of Gothenburg and Chalmers University of Technology in Sweden. He is the founder, chairman, and CEO of Shenzhen Beike Biotechnology Co., Ltd. He also serves as director of the Shenzhen Beike Cell Engineering Institute.
He was among the first experts recognized by China’s Thousand Talents Program. At Beike, he leads the development and commercialization of adult stem cell therapies. His work focuses on conditions of the brain and spinal cord, and on neurodegenerative and autoimmune disorders. His goal is to make high-quality care more accessible.